Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9917266 | 0.91 | RXFP1 (0.44) | MEN1KMT2ASMN1; SMN2L3MBTL1RXFP1 | |
| SCHEMBL12848669 | 0.89 | MEN1 (0.51) | MEN1KMT2ASMN1; SMN2L3MBTL1POLB | |
| SCHEMBL1755636 | 0.86 | KMT2A (0.49) | MEN1KMT2ASMN1; SMN2L3MBTL1POLB | |
| SCHEMBL12452412 | 0.86 | SMN1; SMN2 (0.49) | MEN1KMT2ASMN1; SMN2L3MBTL1POLB | |
| SCHEMBL1753582 | 0.85 | MEN1 (0.54) | MEN1KMT2ASMN1; SMN2L3MBTL1POLB | |
| SCHEMBL13596292 | 0.85 | MEN1 (0.54) | MEN1KMT2ASMN1; SMN2L3MBTL1POLB | |
| SCHEMBL13596299 | 0.85 | MEN1 (0.54) | MEN1KMT2ASMN1; SMN2L3MBTL1POLB | |
| SCHEMBL19901428 | 0.85 | MEN1 (0.54) | MEN1KMT2ASMN1; SMN2L3MBTL1POLB | |
| SCHEMBL19592560 | 0.83 | SMN1; SMN2 (0.55) | MEN1KMT2ASMN1; SMN2L3MBTL1POLB | |
| SCHEMBL19491612 | 0.83 | KMT2A (0.58) | MEN1KMT2ASMN1; SMN2L3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230256109-A1 | Trans-Cyclooctene Bioorthogonal Agents and Uses in Cancer and Immunotherapy | TAMBO, INC. | 2023-08-17 | — | — | US | disclosed |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2021-07-06 | — | — | US | disclosed |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-17 | — | — | US | disclosed |
| US-20170274090-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2017-09-28 | — | — | US | disclosed |
| US-8940784-B2 | Water-soluble CC-1065 analogs and their conjugates | SYNTARGA B.V. (NL) | 2015-01-27 | — | — | US | disclosed |
| US-8158590-B2 | Triazole-containing releasable linkers, conjugates thereof, and methods of preparation | SYNTARGA B.V. (NL) | 2012-04-17 | — | — | US | disclosed |
| US-20110065767-A1 | Substituted CC-1065 Analogs and Their Conjugates | SYNTARGA B.V. (NL) | 2011-03-17 | — | — | US | disclosed |
| US-20090318668-A1 | Water-Soluble CC-1065 Analogs and Their Conjugates | Georg-August-Universität Göttingen Stiftung öffentlichen Rechts (ohne Bereich Humanmedizin) (DE) | 2009-12-24 | — | — | US | disclosed |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | BYONDIS B.V. (NL) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170274090-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | MEN1 1237/4885KMT2A 1026/4885SMN1; SMN2 645/4885 |
| US-20090318668-A1 | Water-Soluble CC-1065 Analogs and Their Conjugates | PCNA, DCK, BAD | MEN1 2080/4885KMT2A 1501/4885SMN1; SMN2 383/4885 |
| US-20230256109-A1 | Trans-Cyclooctene Bioorthogonal Agents and Uses in Cancer and Immunotherapy | ICOS, CD74, PBK | MEN1 862/4885KMT2A 3246/4885SMN1; SMN2 4078/4885 |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | PAICS, CD44, TRIM33 | MEN1 581/4885KMT2A 2312/4885SMN1; SMN2 3528/4885 |
| US-20180133316-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | MEN1 1237/4885KMT2A 1026/4885SMN1; SMN2 645/4885 |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | PCNA, DCLRE1A, CDC5L | MEN1 1247/4885KMT2A 1003/4885SMN1; SMN2 646/4885 |
| US-20110065767-A1 | Substituted CC-1065 Analogs and Their Conjugates | PCNA, TOP1, TOP2B | MEN1 1107/4885KMT2A 829/4885SMN1; SMN2 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.